News

Kanuma would be the first approved therapy for these patients if it secures approval from the Ministry. The NDA was based on data from the global, randomized, double-blind,

ZS-9 is an insoluble, non-absorbed zirconium silicate and it has a clearly defined three-dimensional crystalline lattice structure that was designed and engineered to preferentially trap potassium ions. The

The company is developing PRX302 (topsalysin) for the treatment of urological diseases. Around 20 patients will be enrolled in this trial, in which previously secured multi-parametric magnetic resonance

The company said that Stiolto Respimat (tiotropium bromide and olodaterol) is not indicated to treat asthma or acute deterioration of COPD, which is a serious but treatable lung

EastGate is aimed at using drug delivery innovations in the development of improved new formulations and alternative dosage forms of existing biologically active molecules. E-drops has been successfully

With the acquisition, AbbVie will now have access to Pharmacyclics’ Imbruvic11a (ibrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor used to treat hematological cancers. Imbruvica is approved for use

Currently, the company is exploring two combination treatments for relapsed ovarian cancer. As part of this advancement, a Phase II trial of CRLX101 plus Avastin is enrolling patients,

As part of the deal, NeuroVive Asia will get an upfront payment, a conditional milestone payment and royalty on potential future sales in South Korea. The deal will

The acquired business will now be combined with Ergomed’s existing fast growing post-marketing business, PrimeVigilance. The acquisition of Sound Opinion is part of Ergomed’s strategy of strengthening its